Cargando…
P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION
Autores principales: | Gagelmann, N., Badbaran, A., Panagiota, V., Wolschke, C., Ayuk, F., Thol, F., Ditschkowski, M., Cassinat, B., Robin, M., Schroeder, T., Heuser, M., Reinhardt, H. C., Kröger, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429110/ http://dx.doi.org/10.1097/01.HS9.0000846964.70693.96 |
Ejemplares similares
-
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
por: Gagelmann, Nico, et al.
Publicado: (2022) -
High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
por: Gagelmann, Nico, et al.
Publicado: (2022) -
Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023) -
Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
por: Gagelmann, Nico, et al.
Publicado: (2023) -
Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
por: Mannina, Daniele, et al.
Publicado: (2022)